Advances in Treatment of Clear Cell Renal Cell Carcinoma

A panel of 4 experts on renal cell carcinoma introduce themselves and discuss IMDC risk stratification criteria and the evolution of the treatment landscape.

Sumanta Kumar Pal, MD, FASCO, presents the case of a 66-year-old man with metastatic renal cell carcinoma, and the panel provides comprehensive insights on treatment decisions, highlighting the NCCN Guidelines.

Focusing on VEGF TKIs available for the treatment of patients with metastatic renal cell carcinoma, the panel discusses the goals of therapy in the third-line setting.

Sumanta Kumar Pal, MD, FASCO, reviews data from the TIVO-3 study investigating tivozanib in patients with advanced renal cell carcinoma, and the panel offers its impressions on the results.

The panel discusses the lenvatinib plus everolimus regimen for patients with advanced renal cell carcinoma, highlighting clinical trial data on its efficacy and safety profile.

Following a review of the LITESPARK-005 trial, experts on renal cell carcinoma discuss the potential role of belzutifan in the treatment algorithm.

Sumanta Kumar Pal, MD, FASCO, presents the case of a 48-year-old man with renal cell carcinoma, and Rana R. McKay, MD, discusses how she discusses risk of recurrence with patients.

The panel gives an overview of adjuvant immunotherapy options for patients with renal cell carcinoma.

Dr Pal discusses the study design and results of the KEYNOTE-564 trial, and Benjamin Gerendash, MSN, RN, AGACNP-BC, discusses the management of adverse events associated with pembrolizumab.

Experts on renal cell carcinoma discuss how clinical trial data inform treatment decisions, highlighting the negative results from PROSPER, CheckMate 914 Part A, and IMmotion010.

The expert panel concludes with insights on the treatment of patients with renal cell carcinoma who progress following adjuvant therapy.